NCT05194995Active, not recruitingPhase 1/2
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer，advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 27 Dec 2021
- Start date
- 17 Feb 2022
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Allist Pharmaceuticals, Inc.
- Diseases
- Colorectal cancer
- NCT number
- NCT05194995
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 48
- From 17 Feb 2022 to the primary completion date, 30 Apr 2025
- 17 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has brain metastases, except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days
- Active infection requiring systemic treatment within 14 days
- Active HIV, HBV or HCV
- Any severe and/or uncontrolled medical conditions
Lab values
- LVEF\<50% assessed by ECHO
- QT interval \>470 msec
Who the study is looking for
- Participants must be able to provide an archived tumor sample
- Histologically or cytologically confirmed advanced colorectal cancer, advanced small intestinal cancer and advanced appendiceal cancer with KRAS p.G12C mutation
- Must have received at least 1 prior standard therapy
- Must have at least 1 measurable lesion per RECIST v1.1
- Must have adequate organ function
- Must be able to swallow and retain orally administered medication
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (17)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
- The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation.Hum Cell · 2026 · PMID 42384131
- Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials.Lancet Gastroenterol Hepatol · 2026 · PMID 41344351
This page is information, not medical advice. Discuss any trial with your doctor.